口服耐受对实验性卵巢早衰抗透明带抗体的抑制作用研究

Suppression of antibody to zona pellucida of murine premature ovarian failure by oral tolerance

目的:探讨应用口服耐受的方法抑制抗透明带抗体的产生,为卵巢早衰的治疗提供一种新途径。方法:将100只小鼠随机分为对照组、模型组、小剂量治疗组、中剂量治疗组和大剂量治疗组。各治疗组小鼠给予透明带多肽灌胃,剂量分别为每次1μg、10μg和100μg,共7次。灌胃4次后,经皮下注射免疫原建立小鼠自身免疫性卵巢早衰模型。免疫荧光法检测小鼠外周血和卵巢中抗透明带抗体的表达。结果:中剂量和大剂量治疗组小鼠外周血中抗透明带抗体的阳性率分别为15%和45%,明显低于模型组的80%,具有统计学意义(P<0.01)。中剂量治疗组小鼠卵巢中抗透明带抗体的阳性率为20%,明显低于模型组的70%,具有统计学意义(P<0.01)。结论:适当剂量的透明带多肽能够很好地诱导口服耐受、抑制机体抗透明带抗体的产生。

Objective：To study the suppression of antibody to ovarian zona pellucida （ZP） of premature ovarian failure（POF） by oral tolerance. Method： One hundred mice were divided randomly into control group, model group, low dose therapeutic group, middle dose therapeutic group and high dose therapeutic group . The mice of therapeutic groups were fed with peptide of zona pellucida 3 （pZP3） by gastric intubation depending upon pZP3 concentration and tolerance protocol. To establish the animal model of POF, all the mice were immunized subcutaneously with pZP3 after 4 times of oral administration of pZP3. Serum and ovarian antibody to ovarian ZP were detected by immunofluorescence. Result： After being treated, 15% of mice in middle dose therapeutic group presented positive ZP antibody in the serum ,and 45% in high dose therapeutic group,80% in model group respectively. Compared with the model group,serum antibody to ZP of the mice in middle and high dose therapeutic groups decreased significantly （P 〈0.01 ）. Twenty precent of mice in middle dose therapeutic group presented positive ZP antibody in the ovary, and 70% in model group. There was a significant difference between middle dose therapeutic group and model group （P 〈 0.01 ）. Conclusion：Antibody to.ZP can be suppressed by oral administration of pZP3.